BACKGROUND & OBJECTIVE: Measurement of blood tumor markers is the most widely used and convenient method for the diagnosis of colorectal cancer(CRC). This study was to evaluate the diagnostic value of a biochip diagnostic system C12 in the diagnosis of CRC. METHODS: Twelve tumor markers were detected in the sera of 130 pathologically confirmed CRC patients, including carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 242 (CA242), cancer antigen 15-3 (CA15-3), cancer antigen 125 (CA125), prostate specific antigen (PSA), free-PSA(f-PSA), neuron-specific enolase (NSE), human chorionic gonagotropin-beta (beta-HCG), human growth hormone (HGH), and ferritin, using the C12 diagnostic biochip system. The most relevant tumor markers and the most useful combinations of tumor markers were determined. RESULTS: The overall diagnostic rate for the 130 patients was 42.3%; and the diagnostic rates were 13.6%, 39.5%, 38.2% and 68.8%, for stages I, II, III and IV patients, respectively. There was significant difference in the diagnostic rates between stage I and stage IV patients. Among all the 12 markers, CEA had the highest diagnostic rate of 35.4%. Any combinations of the 5 most relevant tumor markers did not significantly improve the diagnostic rate. However, the combination of 4 markers (CEA+f-PSA +CA125+CA242 or CEA+CA19-9+CA125+f-PSA) was as good as 12 markers in terms of diagnosis. CONCLUSIONS: The C12 biochip diagnostic system has some value in the diagnosis of advanced CRC, but its sensitivity for the diagnosis of early CRC is not satisfactory.
BACKGROUND & OBJECTIVE: Measurement of blood tumor markers is the most widely used and convenient method for the diagnosis of colorectal cancer(CRC). This study was to evaluate the diagnostic value of a biochip diagnostic system C12 in the diagnosis of CRC. METHODS: Twelve tumor markers were detected in the sera of 130 pathologically confirmed CRC patients, including carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 242 (CA242), cancer antigen 15-3 (CA15-3), cancer antigen 125 (CA125), prostate specific antigen (PSA), free-PSA(f-PSA), neuron-specific enolase (NSE), human chorionic gonagotropin-beta (beta-HCG), humangrowth hormone (HGH), and ferritin, using the C12 diagnostic biochip system. The most relevant tumor markers and the most useful combinations of tumor markers were determined. RESULTS: The overall diagnostic rate for the 130 patients was 42.3%; and the diagnostic rates were 13.6%, 39.5%, 38.2% and 68.8%, for stages I, II, III and IV patients, respectively. There was significant difference in the diagnostic rates between stage I and stage IV patients. Among all the 12 markers, CEA had the highest diagnostic rate of 35.4%. Any combinations of the 5 most relevant tumor markers did not significantly improve the diagnostic rate. However, the combination of 4 markers (CEA+f-PSA +CA125+CA242 or CEA+CA19-9+CA125+f-PSA) was as good as 12 markers in terms of diagnosis. CONCLUSIONS: The C12 biochip diagnostic system has some value in the diagnosis of advanced CRC, but its sensitivity for the diagnosis of early CRC is not satisfactory.
Authors: Veronika I Butvilovskaya; Sofya B Popletaeva; Vladimir R Chechetkin; Zhanna I Zubtsova; Marya V Tsybulskaya; Larisa O Samokhina; Leonid I Vinnitskii; Aligeydar A Ragimov; Elena I Pozharitskaya; Galina A Grigor Eva; Natalya Y Meshalkina; Svetlana V Golysheva; Nadezhda V Shilova; Nicolai V Bovin; Aleksander S Zasedatelev; Alla Y Rubina Journal: Cancer Med Date: 2016-03-19 Impact factor: 4.452